David C. Montefiori

发表

Breadth of SARS-CoV-2 Neutralization and Protection Induced by a Nanoparticle Vaccine

D. Weissman, Haiyan Chen, Laura L. Sutherland, 2022, bioRxiv.

Host immunity associated with spontaneous suppression of viremia in therapy-naïve young rhesus macaques following neonatal SHIV infection

K. Wiehe, W. Williams, Eric S. Geanes, 2023, Journal of virology.

Development of LIBRA-seq for the guinea pig model system as a tool for the evaluation of antibody responses to multivalent HIV-1 vaccines

I. Georgiev, S. Richardson, Nagarajan Raju, 2023, bioRxiv.

Tracking HIV-1 recombination to resolve its contribution to HIV-1 evolution in natural infection

Ethan Romero-Severson, Bette Korber, Hui Li, 2018, Nature Communications.

In Vivo Treatment with Insulin-like Growth Factor 1 Reduces CCR5 Expression on Vaccine-Induced Activated CD4+ T-Cells

D. Venzon, Giacomo Gorini, V. Galli, 2023, Vaccines.

Interim Report of the Reactogenicity and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 XBB–Containing Vaccines

S. Chalkias, L. Avena, B. Essink, 2024, The Journal of infectious diseases.

Broadly neutralizing antibody induction by non-stabilized SARS-CoV-2 Spike mRNA vaccination in nonhuman primates

Laura L. Sutherland, R. Baric, S. Santra, 2023, bioRxiv.

SARS-CoV-2 recombinant spike ferritin nanoparticle vaccine adjuvanted with Army Liposome Formulation containing monophosphoryl lipid A and QS-21: a phase 1, randomised, double-blind, placebo-controlled, first-in-human clinical trial.

J. Mascola, Gregory D. Gromowski, S. Peel, 2024, The Lancet. Microbe.

Cold sensitivity of the SARS-CoV-2 spike ectodomain

B. Haynes, D. Montefiori, R. Edwards, 2020, bioRxiv.

Vaccine induction of heterologous HIV-1-neutralizing antibody B cell lineages in humans

K. Janowska, G. Ofek, K. Wiehe, 2024, Cell.